Compare KFRC & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KFRC | ASMB |
|---|---|---|
| Founded | 1962 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 578.3M | 499.8M |
| IPO Year | 1995 | 2010 |
| Metric | KFRC | ASMB |
|---|---|---|
| Price | $36.94 | $26.26 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $36.25 | ★ $43.40 |
| AVG Volume (30 Days) | ★ 183.7K | 106.7K |
| Earning Date | 02-02-2026 | 03-19-2026 |
| Dividend Yield | ★ 4.25% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.96 | N/A |
| Revenue | ★ $1,329,007,000.00 | $37,191,000.00 |
| Revenue This Year | $1.20 | $33.33 |
| Revenue Next Year | $4.98 | N/A |
| P/E Ratio | $18.72 | ★ N/A |
| Revenue Growth | N/A | ★ 31.30 |
| 52 Week Low | $24.49 | $7.75 |
| 52 Week High | $55.40 | $39.71 |
| Indicator | KFRC | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 65.51 | 38.88 |
| Support Level | $32.39 | $24.68 |
| Resistance Level | $35.95 | $28.64 |
| Average True Range (ATR) | 1.51 | 1.54 |
| MACD | 0.13 | -0.08 |
| Stochastic Oscillator | 76.44 | 29.80 |
Kforce Inc is a solutions firm specializing in technology, finance and accounting, and other professional staffing services. The company operates two business segments: 1) In technology segment it provides talent solutions with candidates skilled in areas including systems/applications architecture and development, data management and analytics, business and artificial intelligence, machine learning, project and program management, and network architecture and security. 2) In FA segment company offers consultants in traditional finance and accounting roles such as finance, planning and analysis; business intelligence analysis; general accounting; transactional accounting business and cost analysis; and taxation and treasury. The majority of revenue is earned through the technology segment.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.